Emily Voigt, Ph.D.

Principal Scientist and Director, RNA Vaccine Platform

Dr. Emily Voigt leads the RNA Platform team at AAHI, developing thermostable self-amplifying RNA vaccines and therapeutics from early-stage preclinical development and testing through preparation for Phase 1 clinical trials. In her role, Dr. Voigt directs the design, manufacture, and preclinical testing of RNA vaccines for disease targets including yellow fever, Zika, influenza, chikungunya, and SARS-CoV-2 viruses. Working closely with AAHI's Product Development and Characterization, Formulations, and GMP Manufacturing teams, she leads R&D, preclinical testing, and tech transfer activities of the RNA platform. Dr. Voigt's focus is on developing thermostable systemic and mucosally-delivered RNA vaccines, multivalent RNA vaccines, and further enhancement of RNA vaccine technology to induce stronger and longer-lasting immune responses. As the principal RNA scientist on projects for vaccines against Zika, yellow fever, influenza, tuberculosis, and COVID-19, she is responsible for the planning and oversight of multiple major scientific studies and collaborative projects. Dr. Voigt works closely with our Product Development and Characterization team to enable the development of heat-stable RNA vaccines and immunotehrapies that provide durable protection, focusing on improvements to RNA technology that will provide practical solutions for equitable access to vaccines and immunotherapies.

Dr. Voigt is a scientist with 13 years of experience in innate and vaccine immunology. She received her BS in Chemical Engineering from Kansas State University and her PhD in Chemical and Biological Engineering from University of Wisconsin-Madison, where she studied the interactions between replicating RNA viruses and the cells they infect, identifying and quantifying the synergistic interactions between different innate immune signaling pathways. Seh completed her postdoctoral fellowship at the Mayo Clinic's Vaccine Research Group where she gained experience in conducting, analyzing, and publishing clinical studies of human and mouse immune responses to a variety of vaccines. Dr. Voigt joined AAHI in 2018 where her extensive experience in RNA vaccine design and synthesis, viral immunology, and vaccine immunogenicity drives AAHI's RNA platform innovation to enable RNA vaccines and immunotherapies to be equitably accessible to all areas of the world, including resource-limited areas. 

Education

Ph.D., Chemical and Biological Engineering, University of Wisconsin-Madison, 2014

BS, Chemical Engineering, Kansas State University, 2008

Recent Grants and Contracts

Co-Principal Investigator on BARDA-funded project developing an intranasally administered thermostable RNA vaccine against pandemic influenza (Contract No. 75A0121C00087).

Principal Investigator on DoD and BARDA-funded project developing a nasal spray pandemic influenza RNA vaccine candidate through human clinical trials (Contract No. W15QKN-16-9-1002).

Co-Principal Investigator on NIH-funded project developing a single-vial, thermostable chikungunya RNA vaccine candidate through human clinical trials (Contract No. 75N93023C00018).

Key Personnel on NIH-funded project developing a bivalent RNA-based vaccine targeting yellow fever and Zika viruses (Contract No. 75N93019C00059).